February 9, 2021

FDA Approves Posimir for Post-Surgical Pain Relief

The FDA has approved Posimir® (bupivacaine solution) for infiltration use for post-surgical analgesia for the subacromial space under direct arthroscopic visualization (the space above the shoulder’s ball-and-socket joint).

Posimir is an amide local anesthetic that can provide pain relief for up to 72 hours following arthroscopic subacromial decompression (a procedure designed to release tight ligaments in the shoulder).

Posimir is a novel formulation of bupivacaine, a common numbing anesthetic, administered directly to surgical site for single administration only. Posimir should not be diluted or mixed with local anesthetics or other drugs or diluents.

Patients who receive Posimir should avoid additional local anesthetics for 168 hours (seven days) following administration.

Adverse reactions include dizziness, dysgeusia (altered taste), dysuria (discomfort when urinating), headache, hypoesthesia (numbness), paresthesia (tingling), tinnitus, diarrhea, bruising, fever, somnolence, surgical site bleeding, and vomiting.

Workers’ Comprehensive

News and views in workers’ comp

Important news in workers’ comp delivered to your inbox